+ Watch AEGR
on My Watchlist
STOCK WENT UP BY 350 PERCENT IN TWO YEARS.
With AEGR focused on an orphan drug with no alternative treatments available and only a single potential competitor that has significant side effects, AEGR becomes a compelling buy.
IBD EPS, RS, SPROE, Acc ratings plus P/E and div yieldMEDICAL 6 97 --B+, NO EARNINGS
PDUFA + BB
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions